2-Aminoindane

From PsychonautWiki
(Redirected from 2-Aminoindan)
Jump to: navigation, search
2-Aminoindane
Molecular structure of 2-AI
2-AI.svg
Chemical Nomenclature
Common names 2-AI
Systematic name 2,3-Dihydro-1H-inden-2-amine
Class Membership
Psychoactive class Stimulant
Chemical class Amphetamine, Aminoindane
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 3 - 5 mg
Light 5 - 10 mg
Common 10 - 20 mg
Strong 20 - 40 mg
Heavy 40 mg+
Duration
Total 1 - 2 hours
Onset 10 - 30 minutes
After effects 2 - 4 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Summary sheet: 2-Aminoindane

2-Aminoindane (2-AI) is a psychoactive drug and research chemical with stimulant properties. It is an analogue of amphetamine.[1]

Very little is known about this substance, but it has recently become easily accessible through online research chemical vendors where it is being sold as a designer drug.

Chemistry

2-AI, or 2-Aminoindane, is a structural analogue of amphetamine. It features the R3 terminal carbon of the propane chain of amphetamine bound to the benzene ring. This creates an indane group, a bicyclic moeity containing a benzene ring fused to a pentane ring. 2-AI contains an amino group NH2 bound to R2 of the indane ring thus giving it the name 2-aminoindane. 2-AI is structurally analogous to NM-2-AI, lacking the N-substituted methyl group.

Pharmacology

Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based upon its structure and subjective effect similarities to other stimulants such as amphetamine, methamphetamine and 2-FMA. 2-AI most likely acts as both a dopamine and norepinephrine releasing agent. This means it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.

Physical effects
Child.svg

Cognitive effects
User.svg

Visual effects
Eye.svg

After effects
Aftereffects (3).svg

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 2-AI use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 2-AI has very little history of human usage. Anecdotal evidence from people who have tried 2-AI within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other stimulants, the chronic use of 2-AI can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 2-AI develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 2-AI presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of 2-AI all stimulants will have a reduced effect.

Psychosis

Main article: Stimulant psychosis

Abuse of compounds within the stimulant class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions).[2] A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[3][4] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[5]

Dangerous interactions

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Legal issues

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

2-AI is currently believed to be a grey area compound within most parts of the world. This means that it is not known to be specifically illegal within any country, but people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.

  • United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[7]

See also

External links

References

  1. Structural variation and (+)-amphetamine-like discriminative stimulus properties (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/2068194
  2. Treatment for amphetamine psychosis | [1]
  3. Treatment for amphetamine psychosis | [2]
  4. Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
  5. Treatment for amphetamine psychosis | [3]
  6. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
  7. Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted